Glicksmana RM, Metserb U, Vines D, et al. - This study’s findings demonstrate that the prostate-specific membrane antigen (PSMA)-defined oligo recurrent-prostate cancer (PCa) can be rendered biochemical ‘no evidence of disease’ (bNED), a necessary step towards a cure, in 1 of 5 patients receiving metastasis-directed treatment (MDT) alone. Randomized trials are confirmed to ascertain whether MDT +/− systemic agents can expand the curative therapeutic armamentarium for PCa.

• Researchers recruited a total of 72 individuals between May/2017 and July/2019.

• The results showed that 38 (53%) had PSMA-detected oligo recurrent-PCa amenable for MDT.

• The outcomes indicated that 37 (51%) agreed to MDT: 10 and 27 had undergone surgery and SABR, respectively.

• For this study, 15.9 months was the median follow-up (IQR 9.8-19.1).

• The overall response rate was 60%, including 22% rendered bNED among patients receiving MDT.

• They further observed one (2.7%) grade 3 toxicity (intra-operative ureteric injury).